2024
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus
Arends E, Zlei M, Tipton C, Cotic J, Osmani Z, de Bie F, Kamerling S, van Maurik A, Dimelow R, Gregan Y, Fox N, Rabelink T, Roth D, Sanz I, van Dongen J, van Kooten C, Teng Y. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology 2024, 63: 2387-2398. PMID: 38775637, PMCID: PMC11371378, DOI: 10.1093/rheumatology/keae286.Peer-Reviewed Original ResearchMemory B cellsSystemic lupus erythematosusCirculating memory B cellsB cellsLupus nephritisLupus erythematosusAutoreactive memory B cellsMemory B cell subsetsSLE disease activityMemory B cell phenotypeEfficacy of belimumabSerologically active patientsHigh-sensitivity flow cytometryNaive B cellsB-cell traffickingB cell activationInhibition of B cell activationRetrospective meta-analysisBelimumab initiationIntravenous belimumabSubcutaneous belimumabBelimumabDisease activityLymphocyte traffickingAutoimmune diseases
2013
OP0115 Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Disease Activity in Key Organ Systems: Bliss Sub-Populations
Schmitt C, Roth D, Birch H, Kleoudis C, De Vries J. OP0115 Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Disease Activity in Key Organ Systems: Bliss Sub-Populations. Annals Of The Rheumatic Diseases 2013, 72: a90. DOI: 10.1136/annrheumdis-2013-eular.320.Peer-Reviewed Original ResearchSF-36 physical component scoreEfficacy of belimumabPhysician global assessmentHigh disease activityPhysical component scoreSLE patientsSELENA-SLEDAIDisease activityMean physician’s global assessmentSystemic lupus erythematosus patientsSF-36Treating SLE patientsDisease activity groupLupus erythematosus patientsSLE Responder IndexWeeks of treatmentDisease activity criteriaBelimumab doseFACIT-Fatigue scoresLow complementDouble-blindPlus standard carePrimary endpointSecondary endpointsDisease flare